Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-27082026-275837
EXTRAORDINARY
PART II—Section 3—Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 4589]
NEW DELHI, THURSDAY, AUGUST 27, 2026/BHADRA 5, 1948
THE GAZETTE OF INDIA : EXTRAORDINARY
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 27th August, 2026
[PART II—SEC. 3(ii)]
S.O. 4774(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 and
S.O. 3516(E) dated 30th June, 2026 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the
National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes, the price as specified in column
(6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation
specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer
& marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| SI. | Name of the | Strength | Unit | Manufacturer | Retail |
| No. | Formulation / | | | & Marketing Company | Price (₹) |
| | Brand Name | | | | |
+=====+===================================+===================================================+===========+============================================+================+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 1 | Drotaverine | Each film coated tablet contains: | 1 Tablet | M/s Innova Captab Ltd./ M/s | 14.59 |
| | Hydrochloride | Drotaverine Hydrochloride IP 80 | | Zorvia Healthcare Ltd. | |
| | and Mefenamic | mg, Mefenamic Acid IP 250 mg | | | |
| | Acid Tablets | | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 2 | Empagliflozin, | Each film coated bilayer tablet | 1 Tablet | M/s Exemed | 12.27 |
| | Linagliptin and | contains: Empagliflozin 10 mg, | | Pharmaceuticals/ | |
| | Metformin | Linagliptin 5 mg, Metformin | | M/s Macleods | |
| | Hydrochloride | Hydrochloride IP 1000 mg (as | | Pharmaceuticals Ltd. | |
| | Extended-Release | Extended Release) | | | |
| | Tablets | | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 3 | Empagliflozin, | Each film coated bilayer tablet | 1 Tablet | M/s Exemed | 14.33 |
| | Linagliptin and | contains: Empagliflozin 25 mg, | | Pharmaceuticals/ | |
| | Metformin | Linagliptin 5 mg, Metformin | | M/s Macleods | |
| | Hydrochloride | Hydrochloride IP 1000 mg (as | | Pharmaceuticals Ltd. | |
| | Extended-Release | Extended Release) | | | |
| | Tablets | | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 4 | Escitalopram | Each Mouth Dissolving tablet | 1 Tablet | M/s Akums Drugs & | 15.69 |
| | Oxalate and | contains: Escitalopram Oxalate IP | | Pharmaceuticals Ltd. / | |
| | Clonazepam | eq. to Escitalopram 10 mg, | | M/s Mankind Pharma Ltd. | |
| | Mouth Dissolving | Clonazepam IP 0.5 mg | | | |
| | Tablets | | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 5 | Glimepiride | Each uncoated tablet contains: | 1 Tablet | M/s Unison Pharmaceuticals | 12.48 |
| | Tablets | Glimepiride IP 3 mg | | Pvt. Ltd. | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 6 | Glimepiride | Each uncoated tablet contains: | 1 Tablet | M/s Unison Pharmaceuticals | 13.47 |
| | Tablets | Glimepiride IP 4 mg | | Pvt. Ltd. | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 7 | Telmisartan and | Each uncoated bilayered tablet | 1 Tablet | M/s Pure and Cure | 13.08 |
| | Amlodipine | contains: Telmisartan IP 40 mg, | | Healthcare Pvt. Ltd./ | |
| | Tablets | Amlodipine Besilate IP eq. | | M/s Sun Pharmaceutical | |
| | | Amlodipine 5 mg | | Industries Ltd. | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 8 | Telmisartan and | Each film coated tablet contains: | 1 Tablet | M/s Pure and Cure | 13.27 |
| | Chlorthalidone | Telmisartan IP 40 mg, | | Healthcare Pvt. Ltd./ | |
| | Tablets | Chlorthalidone IP 12.5 mg | | M/s Sun Pharmaceutical | |
| | | | | Industries Ltd. | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 9 | Thiocolchicoside, | Each film coated tablet contains: | 1 Tablet | M/s Ravenbhel Healthcare | 19.74 |
| | Aceclofenac & | Thiocolchicoside IP 4 mg, | | Pvt. Ltd./ | |
| | Paracetamol | Aceclofenac IP 100 mg, | | M/s Seagull | |
| | Tablets | Paracetamol IP 325 mg | | Pharmaceuticals Pvt. Ltd | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 10 | Voglibose and | Each uncoated bilayered tablet | 1 Tablet | M/s Pure and Cure | 13.55 |
| | Metformin | contains: Voglibose IP 0.3 mg, | | Healthcare Pvt. Ltd./ | |
| | Hydrochloride | Metformin Hydrochloride IP 500 | | M/s Alkem Wellness Ltd. | |
| | (SR)Tablets | mg (as sustained release) | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
| 11 | Dolutegravir, | Each film coated tablet contains: | 1 Tablet | M/s Emcure | 120.07 |
| | Lamivudine and | Lamivudine IP 300 mg, Tenofovir | | Pharmaceuticals Ltd. | |
| | Tenofovir | Alafenamide Fumarate IP eq. to | | | |
| | Alafenamide | Tenofovir Alafenamide 25 mg, | | | |
| | Tablets | Dolutegravir Sodium IP eq. to | | | |
| | | Dolutegravir 50 mg | | | |
+-----+-----------------------------------+---------------------------------------------------+-----------+--------------------------------------------+----------------+
Notes:
(a) The manufacturer, as mentioned in column (5) of the table above, of formulations i.e., "new drug" under
paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price not exceeding the price as specified in column
(6) of the table above.
(b) Any other existing manufacturer launching the same new drug as specified in column (2), (3) and (4) of table
above within twelve months of the date of publication of this notification in the Official Gazette is permitted
to do so at a retail price not exceeding the price as specified in column (6) of the table above subject to filing
of Form-IA on IPDMS 2.0 along with supporting documents within one month of launch.
(c) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
[PN/282/150/2026F/F. No. 8(150)/2026/D.P./NPPA-Div.-II]
BHIVA RAM YADAV, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
Login to read full text